Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’
Topline Phase III Data Showed Mixed Induction Results, Maintenance Miss
• By Sten Stovall
Etrolizumab represents Roche's first attempt at ulcerative colitis and Crohn’s disease • Source: Shutterstock 
